Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ardelyx Inc's Business Segments
Ardelyx Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 94
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 94 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product98.8%
- Product, Ibsrela74.2%
- Product, Xphozah24.7%
- Product and Service, Other1.2%
- Non-Cash Royalty Related to Sale of Future Royalties0.7%
- Product supply revenue0.4%
- License0.1%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 93 | 98.8% |
| Product, Ibsrela | $ 70 | 74.2% |
| Product, Xphozah | $ 23 | 24.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
4 more categories available
Sign in to unlock the full Ardelyx Inc dataset.
Description of Ardelyx Inc
Ardelyx Inc. is a biopharmaceutical company based in Fremont, California, that is focused on the development and commercialization of innovative medicines for the treatment of kidney and gastrointestinal diseases. The company was founded in 2007 and has since made significant advancements in the field of biopharmaceuticals.
Ardelyx is driven by the vision of improving the lives of patients suffering from debilitating conditions. They aim to create transformative, targeted, and novel medicines that address the underlying causes of diseases, especially in the areas of nephrology and gastroenterology.
One of the core areas of expertise for Ardelyx is the development of small molecule therapeutics that focus on manipulating the gut and renal physiology to treat a range of diseases. The company's drug development platform utilizes two key concepts: the gastrointestinal tract as a drug target and the gut microbiome as a therapeutic modality.
Ardelyx has successfully developed a proprietary drug discovery platform called NuMET (Nuclear Gut Metabolic Drivers) that enables the identification of novel drug targets and the creation of small-molecule drugs that specifically modulate those targets. This unique approach enables the company to develop medicines that have the potential to treat various diseases with high unmet medical needs.
The company's lead product candidate, tenapanor, is an oral, small molecule inhibitor of the sodium/hydrogen exchanger 3 (NHE3), which is a target involved in the absorption of sodium and the transport of water in the kidneys and intestines. Tenapanor has demonstrated promising results in multiple clinical trials for conditions such as hyperphosphatemia in end-stage kidney disease patients on dialysis, irritable bowel syndrome with constipation (IBS-C), and hyperkalemia, which is an electrolyte imbalance that can be life-threatening.
Ardelyx has a robust pipeline beyond tenapanor, with several other drug candidates in various stages of development. Some of these candidates include RDX013, a small molecule potassium binder for the treatment of hyperkalemia, and RDX8940, a gut-targeted agonist of the TGR5 receptor for the treatment of bile acid malabsorption and other gastrointestinal conditions.
In addition to their drug development efforts, Ardelyx has also established strategic partnerships with other pharmaceutical companies and academic institutions to further enhance their research and development capabilities. They actively collaborate with experts in the field to explore and advance novel therapeutic approaches.
Overall, Ardelyx Inc. is a cutting-edge biopharmaceutical company dedicated to developing innovative medicines for kidney and gastrointestinal diseases. With their unique drug discovery platform and promising pipeline, the company is well-positioned to make a significant impact on the lives of patients in need.
Ardelyx is driven by the vision of improving the lives of patients suffering from debilitating conditions. They aim to create transformative, targeted, and novel medicines that address the underlying causes of diseases, especially in the areas of nephrology and gastroenterology.
One of the core areas of expertise for Ardelyx is the development of small molecule therapeutics that focus on manipulating the gut and renal physiology to treat a range of diseases. The company's drug development platform utilizes two key concepts: the gastrointestinal tract as a drug target and the gut microbiome as a therapeutic modality.
Ardelyx has successfully developed a proprietary drug discovery platform called NuMET (Nuclear Gut Metabolic Drivers) that enables the identification of novel drug targets and the creation of small-molecule drugs that specifically modulate those targets. This unique approach enables the company to develop medicines that have the potential to treat various diseases with high unmet medical needs.
The company's lead product candidate, tenapanor, is an oral, small molecule inhibitor of the sodium/hydrogen exchanger 3 (NHE3), which is a target involved in the absorption of sodium and the transport of water in the kidneys and intestines. Tenapanor has demonstrated promising results in multiple clinical trials for conditions such as hyperphosphatemia in end-stage kidney disease patients on dialysis, irritable bowel syndrome with constipation (IBS-C), and hyperkalemia, which is an electrolyte imbalance that can be life-threatening.
Ardelyx has a robust pipeline beyond tenapanor, with several other drug candidates in various stages of development. Some of these candidates include RDX013, a small molecule potassium binder for the treatment of hyperkalemia, and RDX8940, a gut-targeted agonist of the TGR5 receptor for the treatment of bile acid malabsorption and other gastrointestinal conditions.
In addition to their drug development efforts, Ardelyx has also established strategic partnerships with other pharmaceutical companies and academic institutions to further enhance their research and development capabilities. They actively collaborate with experts in the field to explore and advance novel therapeutic approaches.
Overall, Ardelyx Inc. is a cutting-edge biopharmaceutical company dedicated to developing innovative medicines for kidney and gastrointestinal diseases. With their unique drug discovery platform and promising pipeline, the company is well-positioned to make a significant impact on the lives of patients in need.
Ardelyx Inc. is a biopharmaceutical company that focuses on the development of innovative therapies for patients with gastrointestinal and kidney diseases. The companys portfolio encompasses a range of segments, products, and services aimed at addressing unmet medical needs in these areas.
Segments
1. Gastrointestinal Diseases: Ardelyx targets various gastrointestinal conditions characterized by dysregulation of the digestive system. This includes product candidates for diseases like chronic constipation, irritable bowel syndrome, and other functional gastrointestinal disorders.
2. Kidney Diseases: The company is heavily invested in developing treatments for chronic kidney disease (CKD), particularly focusing on patients with hyperphosphatemia, a condition that arises from the accumulation of phosphate in the blood, often associated with kidney dysfunction.
3. Metabolic Disorders: Ardelyx also considers broader metabolic conditions that interlink with gastrointestinal and kidney health, researching innovative approaches that could influence patient outcomes.
Products
Commercialized Products
- Tenapanor: This is Ardelyxs lead product, which is marketed as a treatment for patients with irritable bowel syndrome with constipation (IBS-C) and has shown efficacy in reducing abdominal discomfort as well as improving bowel movement frequency. Tenapanor acts by inhibiting the sodium/hydrogen exchanger 3 (NHE3), which plays a crucial role in the absorption of sodium and holds potential benefits for patients with conditions such as excessive sodium absorption and chronic constipation.
Pipeline Candidates
- Phosphate Binders: Ardelyx is developing a novel phosphate binder designed for patients with hyperphosphatemia due to CKD. This product aims to effectively lower serum phosphorus levels without the dietary restrictions typically associated with traditional phosphate binders.
- Additional Indications: There may be multiple ongoing studies into various indications related to gastrointestinal and renal health, including conditions that could benefit from modulation of the gut microbiome and associated pathways.
Services
In addition to its pharmaceutical products, Ardelyx may offer a variety of services aimed at healthcare professionals and patients:
1. Patient Support Programs: These programs are designed to help patients effectively manage their conditions and treatment regimens. This can include education on medication usage, dietary advice, and available resources to enhance adherence to therapy.
2. Clinical Trial Participation: Ardelyx conducts clinical trials and may collaborate with healthcare providers and institutions to advance research in gastrointestinal and renal disease, thus enabling better treatment options for patients.
3. Educational Initiatives: The company often engages healthcare providers through educational initiatives that highlight the importance of addressing unmet needs in gastrointestinal and kidney health.
4. Collaborations: Ardelyx may partner with other biotech or pharmaceutical companies, research institutions, and advocacy organizations to foster innovation and leverage resources for developing novel therapeutic solutions.
Focus on Innovation
Ardelyx is keenly focused on leveraging scientific advancements and understanding patient needs. By concentrating on mechanisms of action that are well-studied yet underutilized in therapeutic settings (like NHE3 inhibition), Ardelyx seeks to establish new standards of care in the treatment of gastrointestinal and kidney diseases.
Conclusion
In summary, Ardelyx Inc. is committed to pioneering therapeutic solutions that address significant health challenges in the fields of gastrointestinal and kidney disease. Through its innovative product candidates and comprehensive support services aimed at both healthcare providers and patients, the company strives to make a meaningful impact in the lives of those affected by these conditions.
Segments
1. Gastrointestinal Diseases: Ardelyx targets various gastrointestinal conditions characterized by dysregulation of the digestive system. This includes product candidates for diseases like chronic constipation, irritable bowel syndrome, and other functional gastrointestinal disorders.
2. Kidney Diseases: The company is heavily invested in developing treatments for chronic kidney disease (CKD), particularly focusing on patients with hyperphosphatemia, a condition that arises from the accumulation of phosphate in the blood, often associated with kidney dysfunction.
3. Metabolic Disorders: Ardelyx also considers broader metabolic conditions that interlink with gastrointestinal and kidney health, researching innovative approaches that could influence patient outcomes.
Products
Commercialized Products
- Tenapanor: This is Ardelyxs lead product, which is marketed as a treatment for patients with irritable bowel syndrome with constipation (IBS-C) and has shown efficacy in reducing abdominal discomfort as well as improving bowel movement frequency. Tenapanor acts by inhibiting the sodium/hydrogen exchanger 3 (NHE3), which plays a crucial role in the absorption of sodium and holds potential benefits for patients with conditions such as excessive sodium absorption and chronic constipation.
Pipeline Candidates
- Phosphate Binders: Ardelyx is developing a novel phosphate binder designed for patients with hyperphosphatemia due to CKD. This product aims to effectively lower serum phosphorus levels without the dietary restrictions typically associated with traditional phosphate binders.
- Additional Indications: There may be multiple ongoing studies into various indications related to gastrointestinal and renal health, including conditions that could benefit from modulation of the gut microbiome and associated pathways.
Services
In addition to its pharmaceutical products, Ardelyx may offer a variety of services aimed at healthcare professionals and patients:
1. Patient Support Programs: These programs are designed to help patients effectively manage their conditions and treatment regimens. This can include education on medication usage, dietary advice, and available resources to enhance adherence to therapy.
2. Clinical Trial Participation: Ardelyx conducts clinical trials and may collaborate with healthcare providers and institutions to advance research in gastrointestinal and renal disease, thus enabling better treatment options for patients.
3. Educational Initiatives: The company often engages healthcare providers through educational initiatives that highlight the importance of addressing unmet needs in gastrointestinal and kidney health.
4. Collaborations: Ardelyx may partner with other biotech or pharmaceutical companies, research institutions, and advocacy organizations to foster innovation and leverage resources for developing novel therapeutic solutions.
Focus on Innovation
Ardelyx is keenly focused on leveraging scientific advancements and understanding patient needs. By concentrating on mechanisms of action that are well-studied yet underutilized in therapeutic settings (like NHE3 inhibition), Ardelyx seeks to establish new standards of care in the treatment of gastrointestinal and kidney diseases.
Conclusion
In summary, Ardelyx Inc. is committed to pioneering therapeutic solutions that address significant health challenges in the fields of gastrointestinal and kidney disease. Through its innovative product candidates and comprehensive support services aimed at both healthcare providers and patients, the company strives to make a meaningful impact in the lives of those affected by these conditions.